Draper Asset Management LLC purchased a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 3,692 shares of the company’s stock, valued at approximately $209,000.
A number of other hedge funds also recently made changes to their positions in EDIT. Dimensional Fund Advisors LP raised its position in Editas Medicine by 500.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 110,518 shares of the company’s stock valued at $7,748,000 after acquiring an additional 92,108 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Editas Medicine in the first quarter valued at approximately $261,000. US Bancorp DE grew its holdings in Editas Medicine by 43.8% in the first quarter. US Bancorp DE now owns 13,133 shares of the company’s stock valued at $551,000 after purchasing an additional 4,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Editas Medicine by 42.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,840 shares of the company’s stock valued at $581,000 after purchasing an additional 4,112 shares during the period. Finally, Commonwealth Equity Services LLC grew its holdings in Editas Medicine by 4.7% in the first quarter. Commonwealth Equity Services LLC now owns 19,790 shares of the company’s stock valued at $831,000 after purchasing an additional 891 shares during the period. Institutional investors own 75.81% of the company’s stock.
In other news, CFO Michelle Robertson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 28th. The shares were sold at an average price of $50.00, for a total value of $125,000.00. 0.44% of the stock is currently owned by insiders.
Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Wednesday, August 4th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $0.38 million during the quarter, compared to the consensus estimate of $6.78 million. Editas Medicine had a negative net margin of 205.41% and a negative return on equity of 31.96%. The company’s quarterly revenue was down 96.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.43) EPS. As a group, analysts forecast that Editas Medicine, Inc. will post -3.59 earnings per share for the current year.
Several analysts have commented on the company. Chardan Capital reissued a “buy” rating on shares of Editas Medicine in a report on Wednesday, July 7th. Truist Securities raised Editas Medicine from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $45.00 to $80.00 in a research note on Monday, August 9th. Oppenheimer upgraded Editas Medicine from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $42.00 to $80.00 in a research report on Thursday, September 9th. Truist upgraded Editas Medicine from a “hold” rating to a “buy” rating and lifted their target price for the company from $45.00 to $80.00 in a research report on Monday, August 9th. They noted that the move was a valuation call. Finally, Truist Financial upgraded Editas Medicine to a “buy” rating and set a $80.00 price objective on the stock in a report on Monday, August 9th. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Editas Medicine presently has an average rating of “Hold” and a consensus price target of $56.53.
Editas Medicine Profile
Editas Medicine, Inc engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.
Recommended Story: What is the quiet period?
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDIT).
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.